Qingdao Huanuo Pharmaceutical Biotechnology

Qingdao Huanuo Pharmaceutical Biotechnology is a biotechnology company based in Qingdao, China, founded in 2002. The company specialized in the development of humanized antibodies, particularly focusing on infectious diseases. Its most notable project was the development of a human-derived anti-tetanus exotoxin antibody (HTAT-Fab) using immune phage antibody library technology, a project conducted in collaboration with Shandong University. The antibody was designed to replace traditional horse-derived antitoxins to minimize allergic reactions and provide a more reliable treatment for tetanus. Although the company successfully patented its lead candidate in 2008, the patent subsequently expired, and the company appears to be currently inactive.